CA-SCIENTIST.COM
18.5.2020 08:57:09 CEST | Business Wire | Press release
Scientist.com, the pharma industry’s leading marketplace for outsourced research, announced today that it has joined with the UKCRC Tissue Directory and Coordination Centre (TDCC) to host a panel of experts to discuss current challenges in UK biobanking. The second webinar in the two-part series is scheduled for May 20, 2020, at 2:00 pm BST and will focus on how to enable biobanks to increase sample access in a transparent and compliant manner.
“We are excited to have assembled such distinguished panels on one of the most important topics within the UK biobanking community today—how biobanks can make their samples available to a wider audience for the use of drug discovery,” said Matt McLoughlin, VP of Compliance & Categories at Scientist.com. “It is critical that biobanks in the UK find simpler and more effective ways to connect with the research community to make human biospecimens available for pre-clinical and clinical research.”
The panel consist of experts in biobanking, including Phil Quinlan, PhD, Director at UKCRC TDCC; Alison Parry-Jones, PhD, Operations Director at Wales Cancer Bank; and Matt McLoughlin, VP of Compliance & Categories at Scientist.com.
Register for the free webinar, Overcoming Challenges in UK Biobanking, Part 2: Three Practical Approaches , scheduled for Wednesday May 20, 2020 at 2:00 pm BST.
The entire recording of Part 1: Maximizing the Use, Value and Impact of Human Samples , including highlights from the Q&A section, can be viewed on the UKCRC TDCC webinar debrief .
About Scientist.com
Scientist.com is the pharmaceutical industry’s leading AI-powered marketplace for outsourced R&D. The marketplace simplifies R&D sourcing, saving time and money, reducing risk and providing access to the latest innovative tools and technologies. Scientist.com operates private enterprise marketplaces for most of the world’s major pharmaceutical companies, the Biotechnology Innovation Organization (BIO) and the US National Institutes of Health (NIH). Since its founding in 2007, Scientist.com has raised $39 million from 5AM Ventures, Leerink Transformation Partners and Heritage Provider Network among others.
Visit scientist.com to learn more.
Join Scientist.com on social media: LinkedIn , Twitter , YouTube , Facebook and Instagram .
About the UKCRC Tissue Directory and Coordination Centre
The mission of the UKCRC Tissue Directory and Coordination Centre (UKCRC TDCC) is to maximise the use, value and impact of the UK's human sample resources in the UK, and beyond. The UKCRC TDCC host a world-leading, research-enabling, and networked biobanking infrastructure to facilitate the discovery and use of the UK's human samples and data.
Run by a dedicated team across the University of Nottingham and University College London, the creation of the UKCRC TDCC was mandated by the UK Clinical Research Collaboration via their Vision for Human Tissue Resources. The UKCRC TDCC works to help researchers discover samples and data, help sample resources improve their data systems for sharing, and harmonise policy relating to the discovery and use of samples and data.
The work of the UKCRC TDCC is guided by the belief that the biomedical research ecosystem should be based on open standards, open-science, and pre-competitive collaboration.
The UKCRC TDCC also acts as the UK node for the European research infrastructure for biobanking, BBMRI-ERIC .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200517005040/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G Nfl Blood Assay17.3.2026 07:00:00 CET | Press release
H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Europe N.V. has obtained a CE Certificate of the Lumipulse G NfL Blood assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the quantitative measurement of Neurofilament light chain (NfL) in plasma and serum. “While our assay menu already features many powerful disease-specific biomarkers, NfL marks a major breakthrough: our first CE-marked blood test that empowers clinicians with insights across a wide range of neurological disorders,” said Christiaan De Wilde, CEO at Fujirebio Europe N.V. “We are excited to bring this test to our customers, further expanding our comprehensive portfolio of fully automated neurological disease testing solutions on the LUMIPULSE G platform. We continue to partner with organizations and clinical experts across the wor
H2SITE Appoints Javier Cavada as New Chairman of the Board of Directors17.3.2026 07:00:00 CET | Press release
H2SITE, a technology company delivering hydrogen production and separation solutions, announces the appointment of Javier Cavada as the new Chairman of the Board of Directors. Javier joins H2SITE at a strategic phase of accelerated industrial deployment and scale-up of its hydrogen solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316654723/en/ With more than 25 years of international leadership in the energy and industrial sectors, Javier brings extensive experience in industrialising complex technologies, building high-performance organisations, and scaling large-scale energy platforms. He currently serves as President and Chief Executive Officer of Mitsubishi Power EMEA. His track record also includes serving as CEO and President of Highview Power, as well as spending 17 years at Wärtsilä Corporation, where he held senior executive roles including President of the Energy division and a member of the global Exec
AMWC 2026: Galderma Showcases Category‑leading Innovation With a Comprehensive Portfolio and Holistic, Future‑focused Aesthetic Strategies17.3.2026 07:00:00 CET | Press release
Galderma will present nine posters spanning its full aesthetics portfolio at AMWC 2026, highlighting the regenerative benefits of Sculptra®, the long-lasting efficacy of Restylane®, and the advanced clinical performance of Relfydess® (RelabotulinumtoxinA) 1-9 The data reinforce Galderma’s future-focused approach to innovation, addressing emerging patient needs from menopause‑related skin changes to rising interest in body injectables and regenerative treatments A series of symposia and Masterclasses will further highlight Galderma’s leadership in aesthetics, showcasing how the portfolio supports complex patient profiles and evolving global trends Galderma (SIX: GALD) will present nine abstracts at the Aesthetic & Anti‑Aging Medicine (AMWC) World Congress 2026 in Monaco, showcasing innovative and robust scientific data across its aesthetics portfolio, alongside three symposia, and multiple Masterclasses and Meet‑the‑Expert sessions, all highlighting the expanding benefits of Sculptra, R
Miro Announces Asia Hub in Singapore to Accelerate Growth Across the Region and Bring AI Collaboration to New Markets17.3.2026 02:00:00 CET | Press release
AI Innovation Workspace perfectly placed to help organisations maximise AI investment and accelerate innovation Miro®, the AI Innovation Workspace for teams, today announced plans to expand its operations in Asia, supporting organisations across the region in their AI transformation journey. Miro is investing in people, resources, and infrastructure as it targets growth in key markets, including Singapore, India, South Korea, and other Southeast Asia countries. As the global innovation centre of gravity shifts toward Asia – where R&D spending reached 45% of global investment in 2024 – the organisations leading this charge need tools and platforms built for the complexity and pace of modern innovation and collaboration. Miro's AI-powered innovation workspace is uniquely positioned to support this moment. Miro gives organisations the shared context layer they need to move from insight to execution faster than ever before. For Asia's most ambitious innovators, where speed-to-market and cr
IQM and Zurich Instruments Launch Real-Time Quantum Error Correction Demonstrator with NVIDIA NVQLink16.3.2026 22:24:00 CET | Press release
The demonstrator being built in this project delivers a clear path toward scalable and fault-tolerant quantum computers. The joint project integrates IQM’s superconducting quantum processor, Zurich Instruments’ ZQCS Quantum Control System, with the NVIDIA NVQLink platform to enable real-time error correction. This initiative establishes a foundation for standardized enterprise-ready quantum systems, and datacenter deployment. Today, IQM Quantum Computers and Zurich Instruments announce a joint project to build and operate a real-time quantum error correction (QEC) demonstrator, enabled by the NVIDIA NVQLink platform. This project marks a significant milestone toward scalable and fault-tolerant quantum computing designed for enterprise and datacenter deployment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316511715/en/ IQM and Zurich Instruments launch real-time quantum error correction demonstrator with NVIDIA NVQLink
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom